 Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 2 | 1 | 3 | | 1999 | 4 | 2 | 6 | | 2000 | 3 | 1 | 4 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 6 | 2 | 8 | | 2004 | 4 | 6 | 10 | | 2005 | 3 | 11 | 14 | | 2006 | 3 | 7 | 10 | | 2007 | 12 | 12 | 24 | | 2008 | 11 | 8 | 19 | | 2009 | 13 | 19 | 32 | | 2010 | 17 | 8 | 25 | | 2011 | 12 | 10 | 22 | | 2012 | 25 | 4 | 29 | | 2013 | 16 | 14 | 30 | | 2014 | 27 | 12 | 39 | | 2015 | 24 | 9 | 33 | | 2016 | 20 | 14 | 34 | | 2017 | 30 | 20 | 50 | | 2018 | 37 | 18 | 55 | | 2019 | 29 | 14 | 43 | | 2020 | 23 | 38 | 61 | | 2021 | 12 | 36 | 48 | | 2022 | 6 | 43 | 49 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Garg SK, Rodriguez E, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2023 Feb; 25(S1):S207-S216.
-
Garg SK, Grunberger G, Weinstock R, Lawson ML, Hirsch IB, DiMeglio LA, Pop-Busui R, Philis-Tsimikas A, Kipnes M, Liljenquist DR, Brazg RL, Kudva YC, Buckingham BA, McGill JB, Carlson AL, Criego AB, Christiansen MP, Kaiserman KB, Griffin KJ, Forlenza GP, Bode BW, Slover RH, Keiter A, Ling C, Marinos B, Cordero TL, Shin J, Lee SW, Rhinehart AS, Vigersky RA. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial. Diabetes Technol Ther. 2023 Jan; 25(1):1-12.
-
Sherr JL, Schoelwer M, Dos Santos TJ, Reddy L, Biester T, Galderisi A, van Dyk JC, Hilliard ME, Berget C, DiMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes. 2022 12; 23(8):1406-1431.
-
Tauschmann M, Forlenza G, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C, DeSalvo DJ, Laffel LM, Saboo B, Wheeler BJ, Laptev DN, Yarhere I, DiMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022 12; 23(8):1390-1405.
-
Grobbee EJ, de Jong VD, Schrieks IC, Tushuizen ME, Holleboom AG, Tardif JC, Lincoff AM, Schwartz GG, Castro Cabezas M, Grobbee DE. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-a/? agonist aleglitazar. PLoS One. 2022; 17(11):e0277706.
-
Glaser N, Fritsch M, Priyambada L, Rewers A, Cherubini V, Estrada S, Wolfsdorf JI, Codner E. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022 11; 23(7):835-856.
-
Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. Curr Cardiol Rep. 2022 12; 24(12):2043-2056.
-
Lynch CS, Kennedy VC, Tanner AR, Ali A, Winger QA, Rozance PJ, Anthony RV. Impact of Placental SLC2A3 Deficiency during the First-Half of Gestation. Int J Mol Sci. 2022 Oct 19; 23(20).
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
-
Messer LH, Berget C. Hybrid Closed-Loop Systems to Date: Hype Versus Reality. Diabetes Technol Ther. 2023 Jan; 25(1):91-94.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|